Article thumbnail

Differential binding of RSC3 and RSC3Δ371I proteins and their ability to compete for CD4-binding site-specific antibodies in a neutralization assay.

By Valerie Cortez (174813), Bingjie Wang (767714), Adam Dingens (767715), Mitchell M. Chen (767716), Keshet Ronen (37358), Ivelin S. Georgiev (688784), R. Scott McClelland (80194) and Julie Overbaugh (53378)

Abstract

<p>(A) Post-SI plasma from all 21 superinfected women were tested for binding to RSC3 wildtype and RSC3Δ371I mutant gp120. Ratios (wildtype:mutant) of endpoint titers are shown in the far right column, with ratios >3 noted in red. Ratio was not calculated (-) when reciprocal endpoint titers were both <200. (B) QA013 ~5 years post-initial infection plasma tested against Q461d1, Q23, or DU156 alone (black) with the addition of RSC3 wildtype (dark blue) or mutant proteins (light blue).</p

Topics: Biological Sciences, N 332 supersite, Broad Neutralizing Antibody Responses, Single Infection HIV, Computational sera delineation analyses, Nab response, infection, si, polyclonal Nab response, impacts epitope specificity, epitope mapping techniques
Year: 2015
DOI identifier: 10.1371/journal.ppat.1004973.g003
OAI identifier: oai:figshare.com:article/1478482
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://figshare.com/articles/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.